Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Patients With Relapsing Multiple Sclerosis Over 3.5 Years

Wiendl, Heinz; de Seze, Jerome; Bar-Or, Amit; Correale, Jorge; Cross, Anne H.; Kappos, Ludwig; Selmaj, Krzysztof; Winthrop, Kevin; Giacomini, Paul Steven; Sacca, Francesco; Das Gupta, Ayan; Jehl, Valentine; Pingili, Ratnakar; Mancione, Linda; Zielman, Ronald; Hauser, Stephen L.

dc.contributor.author	Wiendl, Heinz
dc.contributor.author	de Seze, Jerome
dc.contributor.author	Bar-Or, Amit
dc.contributor.author	Correale, Jorge
dc.contributor.author	Cross, Anne H.
dc.contributor.author	Kappos, Ludwig
dc.contributor.author	Selmaj, Krzysztof
dc.contributor.author	Winthrop, Kevin
dc.contributor.author	Giacomini, Paul Steven
dc.contributor.author	Sacca, Francesco
dc.contributor.author	Das Gupta, Ayan
dc.contributor.author	Jehl, Valentine
dc.contributor.author	Pingili, Ratnakar
dc.contributor.author	Mancione, Linda
dc.contributor.author	Zielman, Ronald
dc.contributor.author	Hauser, Stephen L.
dc.date.accessioned	2023-01-02T16:26:37Z
dc.date.available	2023-01-02T16:26:37Z
dc.date.issued	2021-10
dc.identifier.citation	Heinz Wiendl, Jérôme de Seze, Amit Bar-Or, Jorge Correale, Anne H. Cross, Ludwig Kappos, Krzysztof Selmaj, Kevin Winthrop, Paul Steven Giacomini, Francesco Sacca, Ayan Das Gupta, Valentine Jehl, Ratnakar Pingili, Linda Mancione, Ronald Zielman, Stephen L. Hauser. Effect of ofatumumab on serum immunoglobulin levels and infection risk in patients with relapsing multiple sclerosis over 3.5 years. 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis 13-15 October 2021 Vienna, Austria.	es_ES
dc.identifier.uri	https://www.medcommshydhosting.com/MSKnowledgecenter/ectrims/2021/posters/P931_ECTRIMS2021.pdf
dc.identifier.uri	https://repositorio.fleni.org.ar/xmlui/handle/123456789/753
dc.description.abstract	Resumen no disponible	es_ES
dc.language.iso	eng	es_ES
dc.publisher	37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis	es_ES
dc.rights	info:eu-repo/semantics/openAccess
dc.rights.uri	https://creativecommons.org/licenses/by/2.5/ar/
dc.subject	Ofatumumab	es_ES
dc.subject	Immunoglobulins	es_ES
dc.subject	Inmunoglobulinas	es_ES
dc.subject	Multiple Sclerosis, Relapsing-Remitting	es_ES
dc.subject	Esclerosis Múltiple Recurrente-Remitente	es_ES
dc.title	Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Patients With Relapsing Multiple Sclerosis Over 3.5 Years	es_ES
dc.type	Presentation	es_ES
dc.type	info:eu-repo/semantics/publishedVersion
dc.description.fil	Fil: Wiendl, Heinz. University of Muenster; Alemania.
dc.description.fil	Fil: de Seze, Jerome. University Hospital of Strasbourg; Francia.
dc.description.fil	Fil: Bar-Or, Amit. University of Pennsylvania; Estados Unidos.
dc.description.fil	Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.
dc.description.fil	Fil: Cross, Anne H. Washington University; Estados Unidos.
dc.description.fil	Fil: Kappos, Ludwig. University of Basel; Suiza.
dc.description.fil	Fil: Selmaj, Krzysztof. University of Warmia & Mazury; Polonia.
dc.description.fil	Fil: Winthrop, Kevin. Oregon Health and Sciences University; Estados Unidos.
dc.description.fil	Fil: Giacomini, Paul Steven. McGill University; Canadá.
dc.description.fil	Fil: Sacca, Francesco. University “Federico II” of Naples; Italia.
dc.description.fil	Fil: Das Gupta, Ayan. Novartis Healthcare; India.
dc.description.fil	Fil: Jehl, Valentine. Novartis Pharma; Suiza.
dc.description.fil	Fil: Pingili, Ratnakar. Novartis Pharmaceuticals Corporation; Estados Unidos.
dc.description.fil	Fil: Mancione, Linda. Novartis Pharmaceuticals Corporation; Estados Unidos.
dc.description.fil	Fil: Zielman, Ronald. Novartis Pharma B.V.; Países Bajos.
dc.description.fil	Fil: Hauser, Stephen L. University of California; Estados Unidos.
dc.relation.ispartofTITLE	ECTRIMS 2021 congress
dc.type.snrd	Presentation	es_ES